| CASE REPORT |
|
| Year : 2019 | Volume
: 6
| Issue : 1 | Page : 50-54 |
|
|
Hyperprogressive disease after nivolumab in a patient with microsatellite instability-high ampullary cancer
Yi-Hsuan Lai1, Shih-Hung Yang2
1 Division of Hematology and Oncology, Department of Internal Medicine, Taipei City Hospital, Renai Branch, Taipei, Taiwan
2 Department of Oncology; Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan
Correspondence Address:
Dr. Shih-Hung Yang
Department of Oncology, National Taiwan University Hospital, No. 7, Chung-Shan South Road, Taipei 10002
Taiwan
 Source of Support: None, Conflict of Interest: None
DOI: 10.4103/JCRP.JCRP_9_18
|
|
|
Ampullary cancer is a rare type of cancer with a limited choice of systemic therapy. Anti-programmed death-1 monoclonal antibodies have shown promising clinical benefits in multiple types of cancer, especially in tumors with microsatellite instability-high (MSI-H)/defective DNA mismatch repair and high tumor mutation burden. We report a case of a 61-year-old woman with MSI-H ampullary cancer who initially had slow progression without chemotherapy after recurrence. She experienced hyperprogressive disease with a dramatic deterioration of liver metastases following a short duration of nivolumab treatment.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
Next article
